141 results on '"Sonke, G. S."'
Search Results
2. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
3. BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
4. Concurrent chemo-endocrine treatment for early hormone-positive breast cancer: a no-go???
5. Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study)
6. Feasibility and outcomes of a goal-directed physical therapy program for patients with metastatic breast cancer
7. Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
8. Cumulative risk of skin cancer in patients with Li-Fraumeni syndrome
9. Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
10. Physical problems, functional limitations, and preferences for physical therapist-guided exercise programs among Dutch patients with metastatic breast cancer: a mixed methods study
11. Peroperative extent of peritoneal metastases affects the surgical outcome and survival in advanced ovarian cancer
12. OVERVIEW OF NON-EPITHELIAL OVARIAN TUMOURS: INCIDENCE AND SURVIVAL IN THE NETHERLANDS: EP1013
13. Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial
14. Enrichment of high-grade tumors in breast cancer gene expression studies
15. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial
16. Patterns and predictors of first and subsequent recurrence in women with early breast cancer
17. Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level
18. The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure
19. The Role of Hyperthermic Intraperitoneal Intraoperative Chemotherapy in Ovarian Cancer
20. Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms
21. Prognostic factors for survival in metastatic breast cancer by hormone receptor status
22. Intraperitoneal treatment for advanced ovarian cancer, the dutch experience. What did we learn?
23. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
24. Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice
25. Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature review
26. A simple system for grading the response of breast cancer to neoadjuvant chemotherapy
27. Incidence of cardiotoxicity over time in patients with HER2-positive metastatic breast cancer on long term treatment with trastuzumab and the potential risk factors
28. Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer.
29. The tolerability of urodynamic studies and flexible cysto-urethroscopy used in the assessment of men with lower urinary tract symptoms
30. High-dose chemotherapy (HDCT) with hematopoietic stem cell transplantation (HSCT) in high-risk breast cancer (BC) patients with ≥4 involved axillary lymph nodes (ALN): 20-year follow-up of a randomized phase 3 study,: Proffered paper (oral presentation) 187O
31. Contemporary risk of local breast cancer recurrence after neo-adjuvant chemotherapy: Results of a population-based cohort study
32. Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.
33. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.
34. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
35. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
36. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
37. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
38. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
39. Overall survival with ribociclib plus fulvestrant in advanced breast cancer
40. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
41. 37P RNA signatures from tumor-educated platelets (TEP) enable detection of early-stage breast cancer.
42. LBA3Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial.
43. 346PRibociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses.
44. 331PRibociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-3.
45. Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.
46. Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.
47. Effect of physical exercise on the hippocampus and global grey matter volume in breast cancer patients: A randomized controlled trial (PAM study).
48. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
49. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
50. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.